Shinsuke Mizoguchi
Kazo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Testicular Leydig Cell Tumor Incidentally Detected on Computed Tomography : A Case Report
Journal: Hinyokika kiyo. Acta urologica Japonica
Published: May 01, 2026
Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.
Journal: Targeted oncology
Published: February 28, 2026
Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma.
Journal: Japanese journal of clinical oncology
Published: January 11, 2026
Midterm Outcomes of Combination Therapy With Immune Checkpoint Inhibitors and VEGFR-TKIs in Real-World Patients With Advanced Renal Cell Carcinoma.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: November 25, 2025
Treatment Profile of First-Line Immune Checkpoint Inhibitor Combination Therapy for Advanced Renal Cell Carcinoma in Patients With End-Stage Renal Disease on Dialysis.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: October 22, 2025
Non-Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors.
Journal: Molecular cancer research : MCR
Published: August 27, 2025
Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma.
Journal: Japanese journal of clinical oncology
Published: June 28, 2025
Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis.
Journal: International urology and nephrology
Published: May 15, 2025
Effect of age on treatment outcomes of first-line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma.
Journal: Geriatrics & gerontology international
Published: March 26, 2025
Comparative Analysis of Outcomes for Patients With Advanced Renal Cell Carcinoma: Immuno-Oncology Era Versus Tyrosine Kinase Inhibitor Era in the IMDC Favorable-risk Group.
Journal: Anticancer research
Published: January 22, 2025
Case Report: complete response to preoperative ipilimumab and nivolumab combination therapy in advanced papillary renal cell carcinoma with inferior vena cava tumor thrombus and multiple metastases.
Journal: Frontiers in oncology
Published: December 18, 2024
Last Updated: 09/26/2026